ArticleClinicoEconomics and outcomes research : CEOR2017

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.

George Dranitsaris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.